Research & Development
Policy & Regulation
Trends & Finance
Guideline: Page 2
Foundation Medicine highlights lung cancer study results
The findings are from the Prospective Clinicogenomic (PCG) study and were published August 5 in the Journal of Thoracic Oncology Clinical and Research Reports.
August 7, 2022
Guardant Health nabs coverage for liquid biopsy MRD test
The Guardant Reveal test detects circulating tumor DNA (ctDNA) in blood after surgery to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy.
August 1, 2022
AACC sees rise in impact of medical laboratory journal
The impact factor places it in the top 2% of 21,430 ranked academic journals and reaffirms that it is the top journal on medical laboratory technology, AACC said.
July 20, 2022
Veracyte genomic test classifies lung cancer risk in study
In a study published in the journal PLOS One, a group of researchers has clinically confirmed that Veracyte's Percepta Genomic Sequencing Classifier (GSC) can accurately classify lung cancer risk from inconclusive samples taken in a bronchoscopy.
July 19, 2022
Mercy Research to offer Grail multicancer blood test
The test, which aims to complement U.S. guideline-recommended cancer screenings, looks for a shared signal present in the bloodstream that has been associated with many cancers.
July 12, 2022
Exact Sciences supports CMS screening policy changes
The CMS Calendar Year 2023 Physician Fee Schedule proposal considers follow-up colonoscopy to an at-home test as a preventative service. The rule would eliminate all costs to Medicare patients for a follow-up colonoscopy following a positive at-home colorectal cancer screening test.
July 10, 2022
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
FDA reissues EUA for Janssen COVID-19 vaccine, includes warning about risks of myocarditis, pericarditis
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test
Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics
Fountain Health Insurance to cover Grail multicancer test
In a clinical study, the Galleri test demonstrated that it detects a shared signal from more than 50 types of cancers. More than 45 of them currently lack recommended screening tests, the firms noted.
June 21, 2022
Study: less than half of pregnant people screened for HCV
Quest noted that the CDC and the U.S. Preventive Services Task Force (USPSTF) published guidelines in early 2020 acknowledging the value of HCV antibody screening in response to growing rates of infection. A significant increase in screening was seen following the guidelines but many patients are still not receiving the recommended testing, Quest noted.
June 12, 2022
ASCO presentation highlights clinical utility of ctDNA testing
Findings from the study were presented Saturday at the annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine.
June 5, 2022
Labcorp launches skin cancer assay
Studies have shown that LAG-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. Labcorp said its LAG-3 IHC method has demonstrated performance suitable for analysis of LAG-3 immune cell expression in clinical melanoma samples in a study published May 9 in the Journal of Clinical Pathology.
May 18, 2022
Diadem highlights new study on AlzoSure test for Alzheimer's
In a retrospective study published online May 17 in the Journal of Prevention of Alzheimer's Disease, researchers reported that AlzoSure Predict achieved an area under the curve (AUC) of more than 0.98 for identifying people who would progress to future symptomatic Alzheimer's disease up to six years before diagnosis.
May 17, 2022
Dalrada Health completes cervical cancer screening kit trial
Results from the trial were published this month in the Indian Society of Perinatology and Reproductive Biology (IJOPARB) journal. Study participants were screened for cervical cancer with cerVIA, which showed an accuracy of 91%, according to the firm. The test is patent-pending, Dalrada said.
April 24, 2022
Page 2 of 8